The Acute Myeloid Leukemia Treatment Market will register a CAGR of approx 8.8% and is expected to reach USD 6.87 Billion during the forecast period 2023-2032. Acute Myeloid Leukemia (AML) stands as a formidable adversary in the realm of oncology, characterized by its rapid progression and high relapse rates. However, within the landscape of cancer therapeutics, advancements are continually...